



Ref. No.: EIKO/BSE/2024-25/55

Date: 24th January, 2025

To,
Corporate Services Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code: 540204

Sub: Outcome of the meeting of the Rights Issue Committee of Board of Directors of Eiko LifeSciences Limited ("Company") held on Friday, 24th January, 2025

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

Dear Sir/ Ma'am,

This is to inform you that the Rights Issue of the Company, vide Letter of Offer filed with the Stock Exchange on July 07, 2023, the in-principal Approval of BSE Limited (BSE) vide letter dated May 5, 2023, First and Final Call Notice dated December 26, 2023 along with corrigendum dated January 01, 2024, First Reminder Notice for payment of First and Final Call Money dated February 14, 2024 and Final Reminder-Cum Forfeiture Call notice dated December 17, 2024

With reference to above, Right Issue Committee of the Board has considered and approved the following:

1. To convert 12,71,303 partly paid-up Equity shares into fully paid-up Equity shares to the eligible shareholders of the Company pursuant to the payment of Rs. 4,00,46,044.50 (Four Crores, Forty-Six Thousand and Forty-Four Rupees and Fifty Paise Only) along with interest @10% p.a. on pro rata basis amounting to Rs. 34,12,142.42 (Thirty-Four Lakhs, Twelve Thousand, One Hundred and Forty-Two Rupees and Forty-Two Paise Only) made with respect to the Final Reminder Cum Forfeiture Notice for payment of First and Final Call money issued by the Company;
2. To forfeit 1,39,591 shares of shareholders of the Company who failed to make payment of Final Reminder cum forfeiture call for payment of First and Final Call money issued by the Company.
3. To make an application to National Securities Depository Limited ("NSDL") and Central Depository Services (India) Limited ("CDSL") for necessary corporate actions.
4. To avail listing and trading of approvals from BSE Limited ("BSE") pursuant to conversion of partly paid-up shares into fully paid equity shares of the company

The meeting commenced at 10:30 AM and concluded at 11:00 A.M.

Please take the same on your record.

Thanking You,
Yours Faithfully,

For Eiko Lifesciences Limited

Chintan Doshi
Company Secretary and Compliance Officer
Membership No: A 36190

Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134

Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604
Mobile No.: +919082668855; Email id: investor.relations@eikolifesciences.com website: www.eikolifesciences.com